百欧海文制药

最新新闻

• 评级变动
  Raymond James Maintains Biohaven(BHVN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/8/27
• Citi Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• BofA Securities Maintains Biohaven(BHVN.US) With Sell Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/9/10
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Boston Scientific (BSX)
  TipRanks · 2026/9/14
• 公司公告
  Biohaven: Biohaven Pharmaceutical Holding Company Ltd. - Anticipated Adjustment Option Symbol: BHVN New Symbol: To be determined
  OCC · 2022/9/13
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)
  TipRanks · 2026/8/28
• CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 公司公告
  Biohaven: Biohaven Pharmaceutical Holding Company Ltd. - Contract Adjustment Option Symbol: BHVN New Symbol: BHVN1
  OCC · 2022/10/3
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)
  TipRanks · 2026/8/12
• J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Raymond James Maintains Biohaven(BHVN.US) With Buy Rating, Announces Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  Analysts' Top Healthcare Picks: Molina Healthcare (MOH), Biohaven Ltd. (BHVN)
  TipRanks · 2026/8/27
• 评级变动
  William Blair Maintains Biohaven(BHVN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Piper Sandler Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/9/30
• 评级变动
  RBC Capital Downgrades Biohaven(BHVN.US) to Hold Rating, Cuts Target Price to $19
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $19 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。